|
Drugmakers to Pay User Fees for EMA’s New Pharmacovigilance Duties
As EU pharmacovigilance legislation takes effect in early July, the European Commission (EC) is outlining how much drugmakers will have to pay for the European Medicines Agency (EMA) to take on the postmarket regulations, according to a new concept paper.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives